Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Esomeprazole Quadruple Therapy PK/Safety Study
NCT04753437Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration for Bismuth at Day 14, Area Under the Plasma Concentration-time Curve During a Dosing Interval tau for Bismuth at Day 14 and 1 more. Started Apr 2021; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04753437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753437.